Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practiceFirst published 25/03/2024 Last updated 25/03/2024 EU PAS number: EUPAS1000000083StudyFinalised